Submit Interim Safety, Efficacy Data: CDSCO Panel Tells Novartis on Crizanlizumab
New Delhi: Reviewing the status of the ongoing studies of Crizanlizumab concentrate for solution for infusion 10mg/mL (100mg/10mL), the Subject Ex…
Lorem Ipsum has been the industry's standard dummy text.
New Delhi: Reviewing the status of the ongoing studies of Crizanlizumab concentrate for solution for infusion 10mg/mL (100mg/10mL), the Subject Ex…
UK: In a recent study published in the European Journal of Nutrition, Javier T. Gonzalez, Department for Health, University of Bath, Bath, UK, soug…
Hand eczema (HE) is a common condition with diverse causes and symptoms. Various treatment options exist, including topical creams. Hand eczema pre…
New Delhi: Expressing serious disappointment towards Patanjali Ayurved for neglecting to submit a response to its notice, the Supreme Court today i…
A recent study published in the Influenza Other Respiratory Viruses journal examined the effectiveness of COVID-19 vaccines across various psychiat…
Japan: A recent study published in Experimental Dermatology has shed light on the impact of 1-year treatment with dupilumab on work productivity in…
Canada: A recent study published in Radiology: Cardiothoracic Imaging has suggested that current and former smoking status are independently associ…
Lorem Ipsum is simply dummy text of the printing and typesetting has been the industry's.